These are GRIN2A and GRIN3A. The implication of both ionotropic and metabotropic glutamate receptors in carcinogenesis and cancer progression is well-known, especially in gliomas, melanomas, and breast and prostate cancers [reviewed in Ref. This evidence concerns the gene GRIN2A and prostate cancer.